Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland. [electronic resource]
Producer: 20171226Description: 234 p. digitalISSN:- 1471-2415
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Female
- Health Care Costs -- statistics & numerical data
- Humans
- Intravitreal Injections -- economics
- Macular Degeneration -- drug therapy
- Male
- Middle Aged
- Ranibizumab -- administration & dosage
- Receptors, Vascular Endothelial Growth Factor -- administration & dosage
- Recombinant Fusion Proteins -- administration & dosage
- Retrospective Studies
- Switzerland
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.